Inhibitor Therapeutics (INTI) Stock Chart & Stock Price History $0.07 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Chart Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Inhibitor Therapeutics Stock Price Performance 5 Day PerformanceN/A1 Month Performance-8.07%3 Month Performance-1.20%6 Month Performance-26.00%Year-To-Date PerformanceN/A1 Year Performance-38.84% Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. INTI Stock Chart for Friday, November, 22, 2024 INTI Chart by TradingView Inhibitor Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/21/2024$0.08$0.07-1.33%$0.08$0.0750,009 shs$12.75 million11/20/2024$0.08$0.08-8.98%$0.08$0.0862,926 shs$12.92 million11/19/2024$0.09$0.08-8.44%$0.09$0.085,000 shs$14.20 million11/18/2024$0.08$0.09+12.50%$0.09$0.0819,318 shs$15.50 million11/15/2024$0.08$0.08$0.08$0.0881,200 shs$13.78 million11/14/2024$0.09$0.08-5.88%$0.08$0.0881,200 shs$13.78 million Get the Latest News and Ratings for INTI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/12/2024$0.09$0.09$0.09$0.09278,501 shs$14.64 million11/11/2024$0.09$0.09-2.30%$0.09$0.09278,501 shs$14.64 million11/08/2024$0.09$0.09-3.23%$0.10$0.0855,499 shs$14.99 million11/07/2024$0.09$0.09+5.76%$0.09$0.081,040 shs$15.49 million11/05/2024$0.09$0.09$0.09$0.092,900 shs$14.64 million11/04/2024$0.09$0.09$0.09$0.092,900 shs$14.64 million11/01/2024$0.09$0.09$0.09$0.0920,000 shs$14.64 million10/31/2024$0.09$0.09-1.62%$0.09$0.0759,160 shs$14.64 million10/30/2024$0.08$0.09+15.20%$0.09$0.0711,985 shs$14.88 million10/29/2024$0.09$0.08-15.73%$0.08$0.0810,000 shs$12.92 million10/28/2024$0.08$0.09+17.11%$0.09$0.0632,774 shs$15.33 million10/25/2024$0.08$0.08-0.65%$0.08$0.0735,500 shs$13.09 million10/24/2024$0.07$0.08+15.56%$0.08$0.08500 shs$13.18 million10/23/2024$0.08$0.07-17.76%$0.07$0.063,700 shs$11.40 million10/22/2024$0.08$0.08$0.08$0.0810,000 shs$13.87 million10/21/2024$0.08$0.08+0.63%$0.08$0.0810,000 shs$13.87 million Related Companies Cue Biopharma Stock Chart JATT Acquisition Stock Chart Precision BioSciences Stock Chart Iterum Therapeutics Stock Chart Shattuck Labs Stock Chart Provectus Biopharmaceuticals Stock Chart Protara Therapeutics Stock Chart Atlantic Coastal Acquisition Corp. II Stock Chart DBV Technologies Stock Chart CalciMedica Stock Chart Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:INTI) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
